Mayoly appoints a new executive committee to support its ambitious development goals

Mayoly Spindler completes the acquisition of Pharm Nature

Mayoly Spindler completed the acquisition of Ipsen’s CHC branch

Mayoly Spindler acquires Pharm Nature and strengthens its position in natural food supplements

Download the press release

Dear all,

I am very pleased to inform you that the Mayoly group has acquired the company BeauTerra, a French laboratory which specializes in the design and marketing of natural and environmentally friendly personal hygiene products, 100% Made in France. This investment in BeauTerra allows us to broaden our dermo-cosmetic offer.

The personal hygiene market currently represents a third of the dermo-cosmetics market in France.

With an increase in consumer sales of 250% and 2.2 million products sold in 2020, BeauTerra was the third largest contributor to last year’s growth in the French dermo-cosmetics market.

An exceptional success (in just 4 years!) which stems from the creativity and responsiveness of its human-scale team and the effectiveness of its business model, which is based on the digitalization of the relationship between the brand and its 3,800 pharmacy customers.

Alongside Hugo Le Morvan, its Founding-Director, as well as his team, Mayoly Spindler will provide BeauTerra access to its strong sales & logistics resources and its expertise in product and regulatory development to successfully pursue the brand’s growth in France, but also on an international level.

The very short-term objectives will be as follows:

• Strengthen BeauTerra’s position in France and develop turnover so that success can continue
• Accelerate the development of the brand by launching new ranges and references
• Select the international countries for which BeauTerra and its development model will be a success

Please find attached the press releases. The operations to enable BeauTerra to benefit from Mayoly Spindler’s strengths & resources have already started and will continue in the forthcoming weeks.

Yours Sincerely,

P.

Download the press release

Positive results of a cost effectiveness study presented at the XXXIst International Workshop on Helicobacter & Microbiota in Inflammation and Cancer on September 14, 2018 in Kaunas (Lithuania). Data show that in patients with uninvestigated dyspepsia, the “Test and Treat” strategy incorporating Urea Breath Test as implemented in Spain is as effective and more cost effective than the Endoscopy-only strategy with regard to dyspepsia relief and gastric cancer prevention.

Press release

There are approximately 100,000 patients in the U.S. with EPI caused by CP according to the National Pancreas Foundation and more than 30,000 patients with EPI caused by cystic fibrosis according to the Cystic Fibrosis Foundation. Patients are currently treated with porcine pancreatic enzyme replacement pills.

BROOKLYN, N.Y., 17 NOV. 2016 (GLOBE NEWSWIRE) ‐‐ AZURRX BIOPHARMA INC. (NASDAQ:AZRX)

(“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that in partnership with Mayoly Spindler, a European pharmaceutical company, the initiation of a Phase II clinical trial evaluating the safety and efficacy of MS1819-SD in patients with exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP).

The open-label, dose escalation Phase II study is being conducted in two sites in Australia

The Royal Adelaide Hospital and Linear Clinical Research in Perth as well as two sites in New Zealand, P3 Research in Wellington and CCST in Christchurch.  The study is projected to enroll approximately 12 patients with EPI caused by chronic pancreatitis over the next several months.  Dr. Quoc Nam Ngyuen, Associate Professor in the Department of Gastroenterology at the Royal Adelaide Hospital is the principal investigator for the study.

The primary objective of this Phase II study is to investigate the safety of escalating doses of MS1819-SD in patients with chronic pancreatitis. The secondary objective is to investigate the efficacy of MS1819-SD in these patients by analysis of the coefficient of fat absorption and its change from baseline. Initial study results from the MS1819-SD Phase II study are expected in the first half of 2017.

Read more

PRESS RELEASE
Paris, Wednesday, October 5, 2016

MAYOLY SPINDLER acquires the Swedish laboratory Kibion and becomes the leading company in the market of detecting and control of Helicobacter pylori infections.

Mayoly Spindler, the independent French benchmark laboratory in gastroenterology and dermocosmetics, is continuing its international development with the acquisition of the young Swedish laboratory Kibion. Mayoly Spindler has there by become the leading company in the market of urea breath tests used to diagnose the presence of Helicobacter pylori and control its eradication.

>Press release in english